Dendreon Corp. (Nasdaq: DNDN): Put These Two Promising Biotech Stocks on Your Watch List
Investment U (November 6th, 2009) Writes:
Put These Two Promising Biotech Stocks on Your Watch List
by Louis Basenese, Small Cap and Special Situations Expert Friday, November 6, 2009: Issue #1132
All the hoopla surrounding the biotech stock, Dendreon Corp. (Nasdaq: DNDN), this year is well deserved.
After all, the market potential for its prostate cancer treatment, Provenge, is significant. This year, 190,000 new cases of prostate cancer are expected, with 27,000 deaths from the disease. That makes it the most common non-skin cancer in the United States and the third most common cancer worldwide.
But Provenge takes a novel approach to treatment. The drug is the first active immunotherapy to improve survival by training a patient’s immune system to attack the cancer. And since it uses the body’s natural defenses, patients only report flu-like symptoms instead of the nasty side effects associated with chemotherapy.
This
...active immunotherapy, Biotech, Brain Cancer, cancer, Cancers, Chemotherapy, Contrarian Perspectives, Dendreon Corp., editor, Europe, Fda, Glioblastoma Multiforme, immunotherapies, Investing Lessons, InvestmentU, Louis Basenese, Maryland, neck cancers, Northwest, Northwest Biotherapeutics, pancreas cancers, Phase1/II, Popularity Increases, Prostate Cancer, prostate cancer care, prostate cancer treatment, skin cancer, UCLA, United States, USD, wall street


![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)



